CaloSyn Pharma, Inc. Dr. Martin Becker, President & CEO

CaloSyn Pharma, Inc. is a private biopharmaceutical company developing intra-articular therapeutics for osteoarthritis (OA). The Company’s therapeutic approach is based on proprietary combinations of ion channel modulators (ICMs) which block the synthesis of the enzymes responsible for cartilage destruction. The Company’s key advantages are:

• Established mode of drug action with potential for disease modification
• Excellent safety profile using sub-therapeutic doses of drugs in clinical use
• Preliminary positive results in patients
• Portfolio of patent applications

CaloSyn’s first therapeutic target will be OA of the knee. The Company is located in Sharon MA and Shreveport LA.